Viridian Therapeutics, Inc.\DE (VRDN) Free Cash Flow (2016 - 2025)
Historic Free Cash Flow for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to -$84.7 million.
- Viridian Therapeutics, Inc.\DE's Free Cash Flow fell 2461.65% to -$84.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$326.3 million, marking a year-over-year decrease of 6529.13%. This contributed to the annual value of -$232.8 million for FY2024, which is 2580.78% down from last year.
- According to the latest figures from Q3 2025, Viridian Therapeutics, Inc.\DE's Free Cash Flow is -$84.7 million, which was down 2461.65% from -$75.4 million recorded in Q2 2025.
- Viridian Therapeutics, Inc.\DE's 5-year Free Cash Flow high stood at -$11.6 million for Q1 2021, and its period low was -$92.7 million during Q1 2025.
- Its 5-year average for Free Cash Flow is -$43.2 million, with a median of -$39.4 million in 2023.
- As far as peak fluctuations go, Viridian Therapeutics, Inc.\DE's Free Cash Flow plummeted by 19337.92% in 2023, and later soared by 2736.19% in 2024.
- Quarter analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Free Cash Flow stood at -$16.6 million in 2021, then tumbled by 106.23% to -$34.3 million in 2022, then fell by 11.01% to -$38.0 million in 2023, then tumbled by 93.04% to -$73.4 million in 2024, then dropped by 15.37% to -$84.7 million in 2025.
- Its Free Cash Flow stands at -$84.7 million for Q3 2025, versus -$75.4 million for Q2 2025 and -$92.7 million for Q1 2025.